An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)

PHASE2CompletedINTERVENTIONAL

Enrollment

210

Participants

Timeline

Start Date

September 30, 2002

Study Completion Date

September 30, 2004

Conditions

Lung DiseasePulmonary Fibrosis

Interventions

DRUG

interferon-gamma 1b

200 mcg, SQ, 3x per week

Trial Locations (1)

University of Washington Medical Center, Seattle